Skip to main content
Clinical Trials/NCT05870514
NCT05870514
Recruiting
Phase 2

Efficacy and Safety of Fospropofol Disodium Versus Propofol for Deep Sedation in Critically Ill Patients

Xiaobo Yang, MD1 site in 1 country60 target enrollmentJune 1, 2023

Overview

Phase
Phase 2
Intervention
Fospropofol disodium for injection
Conditions
Critical Illness
Sponsor
Xiaobo Yang, MD
Enrollment
60
Locations
1
Primary Endpoint
The percentage of time in the target sedation range without rescue sedation
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of fospropofol disodium for injection compared to propofol for deep sedation in mechanically ventilated ICU patients.

Detailed Description

This is a randomized, open-label, small sample study using fospropofol disodium and propofol for deep sedation in mechanically ventilated ICU patients. Subjects are randomized to different treatment groups (including 1 for fospropofol disodium and 1 for propofol). Remifentanil is co-administered with fospropofol or propofol. Efficacy and safety profiles of fospropofol disodium and propofol are to be monitoted.

Registry
clinicaltrials.gov
Start Date
June 1, 2023
End Date
June 1, 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Xiaobo Yang, MD
Responsible Party
Sponsor Investigator
Principal Investigator

Xiaobo Yang, MD

Clinical Professor

Wuhan Union Hospital, China

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 18 and ≤ 80 years; Expected to require deep sedation ≥8 hours; Requirement for deep sedation (a Narcotrend index between 13 and 64).

Exclusion Criteria

  • Body mass index (BMI) \<18 or \>30 kg/m2; Contraindicate or allergic to study drugs; Moribund state; Expected to have a general anesthesia within 8 hours; Myasthenia gravis; Acute hepatitis or serious hepatic dysfunction (Child-Pugh class C); Chronic kidney disease with glomerular filtration rate (GFR) \< 29 ml/min/1.73m2; Systolic blood pressure less than 90 mm Hg after appropriate intravenous volume replacement and continuous infusions of 2 vasopressors; Acute severe neurological disorder and any other condition interfering with RASS assessment; Pregnancy or lactation; Unstable angina; Acute myocardial infarction; Left ventricular ejection fraction less than 30%; Heart rate less than 50 beats/min; Second- or third-degree heart block in the absence of a pacemaker; Alcohol abuse or drug abuse.

Arms & Interventions

Fospropofol disodium for injection

Patients in the experimental group received fospropofol disodium for injection at an initial infusion rate of 10 mg/kg/h and adjusted to maintain a Narcotrend index between 13 and 64.

Intervention: Fospropofol disodium for injection

Propofol

Patients in the active comparator group received propofol at an initial infusion rate of 3 mg/kg/h and adjusted to maintain a Narcotrend index between 13 and 64.

Intervention: Propofol

Outcomes

Primary Outcomes

The percentage of time in the target sedation range without rescue sedation

Time Frame: From start of study to 48 hours

The percentage of time in the target sedation range without rescue sedation

Secondary Outcomes

  • 7-day ventilator free time(From start of study to 7 days)
  • Length of ICU stay(From start of study to 28 days)
  • 28-day mortality(From start of study to 28 days)
  • Adverse events(From start of study to 48 hours)
  • Success rate of extubation within 7 days(From start of study to 7 days)

Study Sites (1)

Loading locations...

Similar Trials